Danaher stock fails to rise on solid earnings — leading us to question what's next

Danaher stock fails to rise on solid earnings — leading us to question what’s next

Danaher shares dropped on Wednesday because Wall Street was not giving the supplier of tools and equipment to drugmakers and hospitals credit for beating its rosy earnings guidance from earlier this month. Revenue for Danaher’s fourth quarter 2025 rose 4.6% year over year to $6.84 billion, exceeding the LSEG-compiled analyst consensus estimate of nearly $6.81…

Read More
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Ray Stevens, chief executive officer of Structure Therapeutics Inc., during a Bloomberg Television interview at the JPMorgan Healthcare Conference in San Francisco, Jan. 12, 2026. Benjamin Fanjoy | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe…

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to…

Read More